Lies Remeijer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lies Remeijer has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Anna Clara Randag
Rotterdam Eye Hospital Rotterdam The Netherlands
1 shared publication Georges Mgm Verjans
HerpeslabNL of the Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- 5 March 2026
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (11) , 1312-1318
Treatment failure in herpes simplex virus type 1 keratitis
Herpes simplex virus type 1 (HSV-1), one of the human herpesviruses, is a frequent cause of recurrent ocular infections. Treatment primarily relies on nucleoside analogues, such as aciclovir (ACV), with or without topical corticosteroids. Treatment failure may be attributed to non-adherence to therapy or inadequate topical corticosteroid dosing, and to a lesser extent to an incorrect diagnosis, coinfection with non-viral pathogens or therapy resistance. ACV resistance (ACV R ) is relatively rare compared with other reasons for treatment failure, but has been documented in 6% of immunocompetent patients with HSV-1 keratitis. ACV R limits the prophylactic and therapeutic efficacy of nucleoside analogues, potentially leading to clinically refractory disease. In this review, we will address the normal pathogenesis of HSV-1 keratitis, the definition and causes of treatment failure in HSV-1 keratitis, a work-up algorithm to be used in the event of treatment failure, the effect of current treatment regimens on the development of ACV R keratitis and treatment options for ACV R keratitis.
- 5 March 2026
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (11) , 1312-1318
Treatment failure in herpes simplex virus type 1 keratitis
Herpes simplex virus type 1 (HSV-1), one of the human herpesviruses, is a frequent cause of recurrent ocular infections. Treatment primarily relies on nucleoside analogues, such as aciclovir (ACV), with or without topical corticosteroids. Treatment failure may be attributed to non-adherence to therapy or inadequate topical corticosteroid dosing, and to a lesser extent to an incorrect diagnosis, coinfection with non-viral pathogens or therapy resistance. ACV resistance (ACV R ) is relatively rare compared with other reasons for treatment failure, but has been documented in 6% of immunocompetent patients with HSV-1 keratitis. ACV R limits the prophylactic and therapeutic efficacy of nucleoside analogues, potentially leading to clinically refractory disease. In this review, we will address the normal pathogenesis of HSV-1 keratitis, the definition and causes of treatment failure in HSV-1 keratitis, a work-up algorithm to be used in the event of treatment failure, the effect of current treatment regimens on the development of ACV R keratitis and treatment options for ACV R keratitis.